Faeth Therapeutics, Inc.
FTHHealthcare|Biotechnology|US
$22.05
+2.13 (+10.69%)
DCF Value
$5.16
Tangible Book / Share
$6.50
Cash / Share
$6.76
Financials
Financial Snapshot
Market Cap
$568.4M
Enterprise Value
$554.4M
Revenue (TTM)
$0.00
Net Income (TTM)
-$211.4M
Cash & Investments
$174.8M
Net Cash
$174.7M
Free Cash Flow (TTM)
-$43.3M
Operating CF (TTM)
-$43.3M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$174.8M
Quarterly Burn
$10.8M
Monthly Burn
$3.6M
Est. Runway
~16.2 quarters
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $653.0K | $251.0K | $16.6M | $147.6M | $107.1M | $65.8M | $41.3M | $21.2M | $174.8M | |
| Operating Cash Flow | -$10.3M | -$8.6M | -$17.7M | -$30.3M | -$39.0M | -$32.0M | -$24.7M | -$20.5M | -$43.3M | |
| Free Cash Flow | -$10.3M | -$8.6M | -$18.9M | -$32.3M | -$39.3M | -$32.2M | -$24.8M | -$20.5M | -$43.3M | |
| Capital Expenditure | -$31.0K | -$53.0K | -$1.2M | -$2.0M | -$321.0K | -$180.0K | -$146.0K | -$16.0K | -$9.0K | |
| Financing Cash Flow | $750.0K | $8.2M | $35.5M | $163.9M | -$287.0K | -$11.2M | -$787.0K | -$645.0K | $184.1M |
R&D Spending
R&D (TTM)
$41.0M
R&D Intensity
—
R&D Growth vs Prior
+274.4%
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $8.2M | $8.3M | $11.9M | $21.7M | $29.6M | $18.3M | $18.6M | $11.0M | $41.0M | |
| SG&A | $4.5M | $4.0M | $7.5M | $15.1M | $17.7M | $18.8M | $12.5M | $11.3M | $42.1M |
Income Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $44.0K | $73.0K | $209.0K | $685.0K | $1.8M | $571.0K | $551.0K | $0.00 | $133.0M | |
| Gross Profit | -$44.0K | -$73.0K | -$209.0K | -$685.0K | -$1.8M | -$571.0K | -$551.0K | $0.00 | -$133.0M | |
| R&D | $8.2M | $8.3M | $11.9M | $21.7M | $29.6M | $18.3M | $18.6M | $11.0M | $41.0M | |
| SG&A | $4.5M | $4.0M | $7.5M | $15.1M | $17.7M | $18.8M | $12.5M | $11.3M | $42.1M | |
| Operating Income | -$12.7M | -$12.4M | -$19.5M | -$37.5M | -$49.1M | -$37.1M | -$31.7M | -$22.3M | -$216.1M | |
| Interest Expense | $327.0K | $2.3M | $1.7M | $670.0K | $219.0K | $144.0K | $90.0K | $32.0K | $3.0K | |
| Pretax Income | -$13.0M | -$16.7M | -$20.1M | -$36.8M | -$48.6M | -$34.1M | -$30.2M | -$21.1M | -$211.4M | |
| Net Income | -$13.0M | -$16.7M | -$20.1M | -$36.8M | -$48.6M | -$34.1M | -$30.2M | -$21.1M | -$211.4M | |
| EPS (Diluted) | -11.49 | -14.01 | -13.21 | -26.56 | -31.65 | -24.40 | -24.01 | -16.72 | -138.82 | |
| EBITDA | -$12.7M | -$14.4M | -$18.2M | -$35.4M | -$47.0M | -$35.6M | -$28.7M | -$20.9M | -$213.0M | |
| Shares Out. (M) | 1.47 | 1.47 | 1.53 | 1.39 | 1.54 | 1.40 | 1.26 | 1.26 | 25.84 |
Balance Sheet
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $653.0K | $251.0K | $16.6M | $7.2M | $17.8M | $13.0M | $10.0M | $8.7M | $14.2M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $140.5M | $89.3M | $52.7M | $31.3M | $12.5M | $160.6M | |
| Total Current Assets | $1.3M | $502.0K | $20.1M | $148.5M | $108.6M | $67.3M | $41.9M | $21.5M | $177.8M | |
| Total Assets | $1.9M | $1.2M | $21.4M | $153.2M | $118.4M | $74.4M | $45.4M | $22.9M | $178.9M | |
| Total Current Liabilities | $2.7M | $21.7M | $4.8M | $4.9M | $9.1M | $5.6M | $5.4M | $4.3M | $11.0M | |
| Long-Term Debt | $4.0M | $0.00 | $567.0K | $0.00 | $0.00 | $0.00 | $0.00 | $59.0K | $0.00 | |
| Total Liabilities | $55.3M | $69.9M | $5.5M | $6.7M | $15.0M | $9.5M | $7.0M | $4.3M | $11.1M | |
| Stockholders' Equity | -$53.5M | -$68.7M | $15.9M | $146.5M | $103.4M | $64.9M | $38.4M | $18.6M | $167.9M | |
| Retained Earnings | -$75.6M | -$92.3M | -$112.4M | -$149.2M | -$197.8M | -$231.9M | -$262.1M | -$283.1M | -$489.8M |
Cash Flow Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.3M | -$8.6M | -$17.7M | -$30.3M | -$39.0M | -$32.0M | -$24.7M | -$20.5M | -$43.3M | |
| Capital Expenditure | -$31.0K | -$53.0K | -$1.2M | -$2.0M | -$321.0K | -$180.0K | -$146.0K | -$16.0K | -$9.0K | |
| Free Cash Flow | -$10.3M | -$8.6M | -$18.9M | -$32.3M | -$39.3M | -$32.2M | -$24.8M | -$20.5M | -$43.3M | |
| Investing Cash Flow | -$31.0K | -$53.0K | -$1.4M | -$143.1M | $49.9M | $38.4M | $22.4M | $19.8M | -$137.2M | |
| Financing Cash Flow | $750.0K | $8.2M | $35.5M | $163.9M | -$287.0K | -$11.2M | -$787.0K | -$645.0K | $184.1M | |
| Issuance of Stock | $0.00 | $154.0K | $0.00 | $140.6M | $342.0K | $48.0K | $34.0K | $7.0K | $1.2M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$10.4M | $0.00 | -$1.0K | $0.00 | |
| Net Debt Issuance | $750.0K | $8.1M | $526.0K | -$255.0K | -$629.0K | -$761.0K | -$811.0K | -$648.0K | -$193.0K | |
| Stock Based Comp. | $1.2M | $0.00 | $1.5M | $5.7M | $5.8M | $4.5M | $3.1M | $1.3M | $26.2M | |
| Net Change in Cash | -$9.6M | -$402.0K | $16.3M | -$9.4M | $10.6M | -$4.8M | -$3.0M | -$1.3M | $3.6M |
Dilution Tracker
Shares Outstanding
26M
5-Year Share Growth
-17.6%
Stock Issuance (TTM)
$1.2M
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 1.47 | 1.47 | 1.53 | 1.39 | 1.54 | 1.40 | 1.26 | 1.26 | 25.84 | |
| Change vs Prior % | — | 0.0% | 4.3% | -9.4% | 10.8% | -9.0% | -10.1% | 0.4% | 1949.6% | |
| Stock Issuance | $0.00 | $154.0K | $0.00 | $140.6M | $342.0K | $48.0K | $34.0K | $7.0K | $1.2M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$10.4M | $0.00 | -$1.0K | $0.00 | |
| Stock Based Comp. | $1.2M | $0.00 | $1.5M | $5.7M | $5.8M | $4.5M | $3.1M | $1.3M | $26.2M |
Margins & Profitability
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | 24.4% | 24.4% | -126.5% | -25.1% | -47.0% | -52.5% | -78.6% | -113.4% | -153.5% | |
| ROA % | -704.8% | -1375.5% | -93.8% | -24.0% | -41.0% | -45.9% | -66.5% | -92.1% | -118.1% | |
| ROIC % | 10888.9% | 279.9% | -117.0% | -25.2% | -44.1% | -52.1% | -75.0% | -110.9% | -128.6% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | -65.9% | -186.3% | -227.8% | -163.9% | 68.4% | 3.5% | 100.0% | |
| Operating Income | 0.0% | 2.4% | -56.4% | -92.7% | -31.0% | 24.5% | 14.6% | 29.6% | |
| Net Income | 0.0% | -28.4% | -20.1% | -83.1% | -32.1% | 29.8% | 11.6% | 30.1% | |
| EPS (Diluted) | 0.0% | -21.9% | 5.7% | -101.1% | -19.2% | 22.9% | 1.6% | 30.4% | |
| Operating Cash Flow | 0.0% | 16.9% | -106.6% | -70.9% | -29.0% | 17.9% | 23.0% | 17.1% | |
| Free Cash Flow | 0.0% | 16.6% | -119.3% | -70.7% | -21.9% | 18.2% | 22.9% | 17.5% | |
| R&D Expense | 0.0% | 1.5% | 42.8% | 81.7% | 36.6% | -38.1% | 1.8% | -41.2% | |
| SG&A Expense | 0.0% | -11.1% | 87.6% | 101.0% | 17.1% | 5.8% | -33.5% | -9.3% | |
| Total Assets | 0.0% | -34.2% | 1660.7% | 615.1% | -22.7% | -37.2% | -39.0% | -49.5% | |
| Book Value / Share | 0.0% | -28.4% | 122.2% | 917.6% | -36.3% | -31.1% | -34.2% | -51.8% | |
| Debt | 0.0% | 238.3% | -95.7% | 243.6% | 241.2% | -22.7% | -38.1% | -60.8% | |
| Diluted Shares | 0.0% | 0.0% | 4.3% | -9.4% | 10.8% | -9.0% | -10.1% | 0.4% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B3.39
10Y Low / Med / High0.30 / 0.72 / 36.38
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$5.16
Tangible Book / Share
$6.50
Net Current Assets / Share
$6.47
Graham Net-Net
$6.34
Cash / Share
$6.76
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -32.90 | -26.98 | -28.61 | -4.37 | -0.94 | -0.57 | -0.41 | -0.64 | -0.16 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -10.36 | -8.07 | 36.38 | 1.10 | 0.44 | 0.30 | 0.32 | 0.72 | 3.39 | |
| EV/EBITDA | -43.98 | -39.56 | -30.89 | -4.40 | -0.77 | -0.35 | -0.21 | -0.30 | -2.60 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
24.12
Safe
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $6.3M |
| Net Income | -$18.4M | -$5.1M | -$5.2M |
| EPS | $-14.70 | $-3.48 | $-3.52 |
| # Analysts (EPS) | 5 | 7 | 10 |